| 1 |
33342939 | Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. | 2022 Jan 1 |
2 |
| 2 |
35052871 | Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study. | 2022 Jan 17 |
1 |
| 3 |
35494422 | The Relationship of Circulating Proprotein Convertase Subtilisin/Kexin Type 9 With TSH and Lipid Profile in Newly Diagnosed Patients With Subclinical and Overt Hypothyroidism. | 2022 |
1 |
| 4 |
35596184 | Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes. | 2022 May 20 |
1 |
| 5 |
32624555 | Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population. | 2021 Apr 1 |
5 |
| 6 |
33546945 | PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction. | 2021 Mar 10 |
1 |
| 7 |
33549441 | Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience. | 2021 Mar 10 |
2 |
| 8 |
33626480 | Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation? | 2021 Apr |
1 |
| 9 |
34041285 | Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study. | 2021 |
1 |
| 10 |
34270402 | Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels Predict Future Cardiovascular Event Risks in Hemodialyzed Black African Patients. | 2021 Jul 20 |
4 |
| 11 |
34336112 | Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients. | 2021 |
1 |
| 12 |
34380558 | Association between the rs615563 variant of PCSK9 gene and circulating lipids and Type 2 diabetes. | 2021 Aug 11 |
1 |
| 13 |
34581425 | Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials. | 2021 Sep 28 |
1 |
| 14 |
34601896 | PCSK9 Activity Is Potentiated Through HDL Binding. | 2021 Nov 12 |
1 |
| 15 |
34754882 | A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia. | 2021 |
2 |
| 16 |
31917184 | Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. | 2020 Jan - Feb |
1 |
| 17 |
32073428 | Triglycerides and residual risk. | 2020 Apr |
1 |
| 18 |
32225075 | Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. | 2020 Mar 26 |
1 |
| 19 |
32469502 | Artificial Platelets for Efficient siRNA Delivery to Clear "Bad Cholesterol". | 2020 Jun 24 |
2 |
| 20 |
32496664 | Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters. | 2020 Sep |
1 |
| 21 |
32862087 | Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. | 2020 Sep |
1 |
| 22 |
32895189 | [The triglyceride-lowering effects of PCSK9 inhibitor differ in patients with different baseline triglyceride levels]. | 2020 Aug 30 |
9 |
| 23 |
33053221 | A Versatile Nonviral Delivery System for Multiplex Gene-Editing in the Liver. | 2020 Nov |
1 |
| 24 |
33060383 | Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin? | 2020 Dec |
1 |
| 25 |
33262707 | PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation. | 2020 |
2 |
| 26 |
33302966 | Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study. | 2020 Dec 10 |
1 |
| 27 |
30910670 | Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. | 2019 May |
1 |
| 28 |
30953636 | Keep recycling going: New approaches to reduce LDL-C. | 2019 Jun |
1 |
| 29 |
31002780 | Circulating PCSK9 concentrations are increased in postmenopausal women with the metabolic syndrome. | 2019 Jul |
1 |
| 30 |
31100024 | An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. | 2019 Jul |
2 |
| 31 |
31441123 | Characterization of LDLR rs5925 and PCSK9 rs505151 genetic variants frequencies in healthy subjects from northern Chile: Influence on plasma lipid levels. | 2019 Nov |
1 |
| 32 |
31480784 | Polymorphisms in PCSK9, LDLR, BCMO1, SLC12A3, and KCNJ1 are Associated with Serum Lipid Profile in Chinese Han Population. | 2019 Sep 2 |
4 |
| 33 |
31550797 | [Predictive value of plasma PCSK9 levels in acute myocardial infarction patients without reperfusion therapy for recurrence of cardiovascular events within 1 year]. | 2019 Sep 17 |
1 |
| 34 |
32021342 | Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes? | 2019 |
3 |
| 35 |
29649884 | The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia. | 2018 Jul |
2 |
| 36 |
29724976 | Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia. | 2018 May |
1 |
| 37 |
30105099 | The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population. | 2018 |
4 |
| 38 |
30205809 | Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population. | 2018 Sep 11 |
2 |
| 39 |
30261472 | Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. | 2018 Nov |
1 |
| 40 |
30275531 | Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. | 2018 Nov |
1 |
| 41 |
30317984 | The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors. | 2018 |
1 |
| 42 |
30326043 | Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. | 2018 Oct 1 |
1 |
| 43 |
30423567 | Acute-Phase Plasma PCSK9 Levels and Recurrent Cardiovascular Events in a Chinese Acute Myocardial Infarction Cohort. | 2018 |
1 |
| 44 |
27804190 | Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes. | 2017 Mar |
1 |
| 45 |
28155622 | The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia. | 2017 |
1 |
| 46 |
28283395 | Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females. | 2017 Nov |
1 |
| 47 |
28391915 | Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism. | 2017 Jan - Feb |
1 |
| 48 |
28450903 | PCSK9 as a therapeutic target for cardiovascular disease. | 2017 Mar |
1 |
| 49 |
28606094 | What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis. | 2017 Jun 12 |
2 |
| 50 |
28673045 | The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response. | 2017 Sep 1 |
2 |